POMDOCTOR Limited Prices IPO on Nasdaq

Oct 8, 2025
POMDOCTOR Limited, a leading online medical services platform in China, has announced the pricing of its initial public offering on Nasdaq, aiming to raise approximately $20 million.

POMDOCTOR Limited, a prominent online medical services platform for chronic diseases in China, has announced the pricing of its initial public offering (IPO) of 5,000,004 American Depositary Shares (ADSs) at $4.00 per ADS. Announced in a press release, the ADSs are set to commence trading on the Nasdaq Global Market under the ticker symbol "POM" on October 8, 2025.

The company expects to generate approximately $20 million in gross proceeds from the offering, excluding underwriting discounts and related expenses. Additionally, POMDOCTOR has granted underwriters an option to purchase up to 750,000 additional ADSs within 45 days at the public offering price, less underwriting discounts.

Joseph Stone Capital, LLC is acting as the underwriter for this offering, which is being conducted on a firm commitment basis. The offering is anticipated to close on or about October 9, 2025, pending customary closing conditions.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.